Pharmagen Announces Hiring of Quality Control Manager

Pharmagen Announces Hiring of Quality Control Manager


SILVER SPRING, Md., Oct. 9, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or "Pharmagen") announces the hiring of Confidence Ekeanyanwu as a Quality Control Manager for its laboratory division. Ms. Ekeanyanwu will lead Pharmagen's efforts to become cGMP complaint ahead of its' Food and Drug Administration (FDA) registration and the pending federal compounding legislation in Congress. She will be responsible for aspects of USP/cGMP compliance, environmental monitoring and quality systems. Confidence comes to Pharmagen from NBTY, Inc. where she was a Micro Biologist II. Previously, she served similar roles at both Teva Pharmaceuticals and PepsiCo.

Mackie Barch, Chief Executive Officer of Pharmagen, commented that "we are very fortunate to find Confidence, as she brings a broad array of quality control experience from both the pharmaceutical and consumer goods industries. She will enable us to strengthen our compliance in an effort to continually exceed both UPS and cGMP requirements. This is just another example of how Pharmagen continues to demonstrate that we put patient safety first."

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.

Contact: 888-264-4597 or [email protected]
Follow Us on Twitter: @pharmagenrx

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Pharmagen, Inc.

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.